Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRINASDAQ:HCMTSE:ITHNASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$1.30-7.1%$1.50$1.10▼$59.34$2.78M-1.68291,265 shs111,953 shsHCMHUTCHMED$16.90-4.6%$14.35$11.51▼$21.50$2.95B0.52100,081 shs159,752 shsITHInternational Tower Hill MinesC$1.27+0.8%C$1.05C$0.57▼C$1.48C$178.30M1.1735,130 shs1,600 shsSOPHSOPHiA GENETICS$2.87-1.0%$2.96$2.58▼$5.05$191.39M154,689 shs49,148 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio0.00%-5.80%-10.34%-78.30%-97.66%HCMHUTCHMED0.00%+10.10%+29.11%+7.71%-5.69%ITHInternational Tower Hill Mines0.00%-3.79%+36.56%+35.11%+73.97%SOPHSOPHiA GENETICS0.00%-8.31%-7.72%-10.87%-40.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRIGRI Bio2.0606 of 5 stars3.52.00.00.01.90.01.3HCMHUTCHMED1.439 of 5 stars2.02.00.00.02.80.01.9ITHInternational Tower Hill MinesN/AN/AN/AN/AN/AN/AN/AN/ASOPHSOPHiA GENETICS1.7995 of 5 stars3.43.00.00.01.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRIGRI Bio 3.00Buy$22.001,592.31% UpsideHCMHUTCHMED 2.00Hold$19.0012.43% UpsideITHInternational Tower Hill Mines 0.00N/AN/AN/ASOPHSOPHiA GENETICS 2.75Moderate Buy$6.80136.93% UpsideCurrent Analyst Ratings BreakdownLatest SOPH, ITH, HCM, and GRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRIGRI BioN/AN/AN/AN/A$5.22 per shareN/AHCMHUTCHMED$630.20M4.67$0.69 per share24.51$4.27 per share3.96ITHInternational Tower Hill MinesN/AN/AC$0.06 per share22.50C$0.29 per shareN/ASOPHSOPHiA GENETICS$67.17M2.85N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRIGRI Bio-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%8/12/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.0011.58N/AN/AN/AN/A6/18/2025 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/ASOPHSOPHiA GENETICS-$78.98M-$1.00N/AN/AN/A-110.71%-55.06%-38.33%8/5/2025 (Estimated)Latest SOPH, ITH, HCM, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRIGRI Bio$1.91146.92%N/AN/A N/AHCMHUTCHMEDN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRIGRI BioN/A3.103.10HCMHUTCHMED0.072.812.68ITHInternational Tower Hill MinesN/A10.3730.48SOPHSOPHiA GENETICS0.123.803.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRIGRI Bio33.95%HCMHUTCHMED8.82%ITHInternational Tower Hill Mines71.80%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipGRIGRI Bio0.13%HCMHUTCHMED3.60%ITHInternational Tower Hill Mines0.51%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRIGRI Bio12.14 million8.92 millionNot OptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableITHInternational Tower Hill Mines220140.40 millionN/ANot OptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableSOPH, ITH, HCM, and GRI HeadlinesRecent News About These CompaniesEnough hype about AI in health—let’s talk about resultsJune 12 at 1:10 AM | fastcompany.comM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3, 2025 | zawya.comM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comM42, partners launch liquid biopsy testing in UAEJune 3, 2025 | tradearabia.comThe Multimodal Imperative: How AI-Driven Technology is Driving Impactful ChangesJune 2, 2025 | fiercepharma.comSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateJune 1, 2025 | marketbeat.com'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearingMay 28, 2025 | israelnationalnews.comHigh Court grants custody of IVF baby to adoptive, not biological parentsMay 12, 2025 | msn.comSOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2025 | uk.finance.yahoo.comSupreme Court: IVF mixup baby to remain with birth parentsMay 12, 2025 | israelnationalnews.comSupreme Court upholds decision to keep IVF child with birth mother following embryo mix-upMay 12, 2025 | msn.comSupreme Court rules birth parents of child born in IVF mix-up are legal parentsMay 12, 2025 | msn.comThe Sophia Case: When Parenthood Isn’t Just About GeneticsMay 10, 2025 | blogs.timesofisrael.comSOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comSophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...May 7, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comSOPHiA GENETICS Reports First Quarter 2025 ResultsMay 6, 2025 | prnewswire.comSOPHiA GENETICS expands AstraZeneca liquid biopsy testApril 30, 2025 | investing.comSOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy WorldwideApril 29, 2025 | msn.comSOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACRApril 28, 2025 | prnewswire.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025April 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationTop 5 Stocks Hedge Funds Are Buying Right NowBy Ryan Hasson | May 20, 2025View Top 5 Stocks Hedge Funds Are Buying Right NowArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t BudgeSOPH, ITH, HCM, and GRI Company DescriptionsGRI Bio NASDAQ:GRI$1.30 -0.10 (-7.14%) As of 06/13/2025 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.HUTCHMED NASDAQ:HCM$16.90 -0.82 (-4.63%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$16.90 +0.01 (+0.03%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.International Tower Hill Mines TSE:ITHC$1.27 +0.01 (+0.79%) As of 06/13/2025 03:39 PM EasternInternational Tower Hill Mines Ltd. engages in the acquisition, exploration, and development of mineral properties. It holds rights to acquire interests in the Livengood gold project covering an area of approximately 19,546 hectares located to the northwest of Fairbanks, Alaska. The company was formerly known as Tower Hill Mines Ltd. and changed its name to International Tower Hill Mines Ltd. in March 1991. International Tower Hill Mines Ltd. was incorporated in 1978 and is headquartered in Vancouver, Canada.SOPHiA GENETICS NASDAQ:SOPH$2.87 -0.03 (-1.03%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.96 +0.09 (+3.14%) As of 06/13/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
